Results from the study, which focused on gynecological malignant tumors, were presented at the Society for Immunotherapy of ...

Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...

More recent acquisitions in 2024—oncology firms Mirati and RayzeBio and neurology firm Karuna—also help support Bristol's strong overall pipeline and wide moat. Bristol has created a strong pipeline ...

We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...

The market is also wondering how Merck may eventually need to find a replacement for its top-selling Keytruda immunotherapy ...

Investors have been hesitant to buy Merck largely due to its dependence on cancer drug Keytruda, which is facing a patent cliff later this decade, posing big question marks about Merck's potential ...

The results will help Keytruda take a further bite out of its ... factor that benefits Merck against BMS as Inlyta will lose its patent protection in 2025 “It would appear that Merck has managed ...

The article " Merck vs. Bristol-Myers: Analyst Views Differ After Q3 Earnings " first appeared on MarketBeat.

Keytruda (pembrolizumab ... The drug is due to lose patent protection in 2028, however, so MSD (known as Merck & Co in the US) has been working to build its oncology pipeline to absorb the ...

The top 20 biopharmaceutical companies demonstrated signs of recovery during the third quarter (Q3) of 2024 as investor ...

We recently made a list of UBS’ Best Stocks In The AI, Growth & Low Rates Era: Top 29 US Stocks. In this piece, we will take ...

Germany’s Bayer saw its shares tumble almost 11% to 21.76 euros this morning, as it reported level third-quarter 2024 sales ...